Five billion dollars for AI-designed medicines: Isomorphic Labs raises the largest biotech sum ever, without a single patient in a trial
The Alphabet subsidiary wants to use the money to scale up its design models and prepare its first drug candidates for clinical testing.
Isomorphic Labs, the Alphabet company that designs new medicines with AI, on Tuesday announced a 5 billion dollar funding round. Greenoaks and Sequoia Capital lead the round, the company itself writes, with Andreessen Horowitz among the new investors and Alphabet, Thrive Capital, GV, Temasek and the UK Sovereign AI Fund investing again. According to BioSpace, it is the largest private financing ever in biotech; the previous record stood at 3 billion dollars, raised by Altos Labs in 2022.
The company raised 2.1 billion dollars as recently as May and 600 million in March 2025, bringing the total to at least 7.7 billion according to BioSpace. Isomorphic did not disclose a valuation. Tech Times points out that Bloomberg earlier reported talks based on a value of around 50 billion dollars, which the company does not confirm. The money goes to its own IsoDDE design engine, a set of simulation models for different disease areas, and to its internal pipeline.
That pipeline is still at an early stage. Isomorphic speaks of positive preclinical results in oncology and immunology and works with Novartis, Eli Lilly and Johnson & Johnson, but according to BioSpace it has not yet made a single compound public and has not started any trial in humans. Chief executive Demis Hassabis had said earlier that those trials would begin by the end of 2026.
Tech Times adds caveats. The claim that IsoDDE outperforms AlphaFold 3 on difficult protein-binding predictions has not been independently tested, and a better prediction of how a molecule binds does not, according to the site, solve why most drug candidates fail in clinical trials: because they do not work or are too toxic. No AI-designed medicine has yet been approved by the US FDA.